- Home
- Â /Â Jounce Therapeutics
Jounce Therapeutics
Stock Price
$1.9
2023-05-05
Market Capitalization
$101.6 M
2023-05-05
Jounce Therapeutics Summary
Company Summary
- Overview
- Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies biomarkers to match the right therapy.Â
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://jouncetx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Hugh Cole, Chief Operating Officer
Kim Drapkin, Chief Financial Officer
Jacqui Fahey Sandell, Chief Legal Officer and Corporate Secretary
Jounce Therapeutics Financials
Summary Financials
- Net income (FY, 2022)
- ($50.9M)
- Cash (FY, 2022)
- $150.6M
- EBIT (FY, 2022)
- ($52.2M)
- Enterprise value
- ($39.0M)